Chromadex Corp expected to post earnings of 2 cents a share - Earnings Preview

Niagen Bioscience

28/02/2025 21:10

Chromadex Corp CDXC.OQ CDXC.O is expected to show a rise in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

The Los Angeles California-based  company is expected to report a 26.1% increase in revenue to $26.733 million from $21.2 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Chromadex Corp is for earnings of 2 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Chromadex Corp is $8.00​, above​ its last closing price of $5.44. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
0.01
0.00
0.02
Beat
500.6
Jun. 30 2024
-0.02
-0.02
0.00
Beat
100
Mar. 31 2024
-0.02
-0.02
-0.01
Beat
40​
Dec. 31 2023
-0.03
-0.03
0.00
Beat
100
​​Sep. 30 2023
-0.03
-0.03
-0.01
Beat
69.2
Jun. 30 2023
-0.04
-0.04
-0.03
Beat
20​
Mar. 31 2023
-0.05
-0.05
-0.03
Beat
37.5
Dec. 31 2022
-0.03
-0.02
-0.02
Met
17.3

This summary was machine generated February 28 at 21:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)